Travatan, eye drops 40 µg/ml 2.5ml

Travatan has an anti-glaucomatous effect. The main active substance of the drug, travoprost, is a synthetic analog of prostaglandin F2-alpha, which selectively activates FP-receptors of the ciliary body and causes increased outflow of intraocular fluid filling the space between the lens and the cornea, which is accompanied by a decrease in intraocular pressure. Travathan predominantly enhances the uveoscleral aqueous outflow pathway with no detectable effect on intraocular fluid production.

The anti-occlusive effect of travoprost appears approximately 120 minutes after instillation of the drug with maximum hypotensive effect within 12 hours.

Pharmacokinetics

Absorption and metabolism

Travoprost is absorbed through the cornea of the eye, where hydrolysis of travoprost to its biologically active form, travoprost acid, occurs.

The Cmax of hervoprost in plasma is reached within 30 minutes after topical application and is 25 pg/ml or less.

Elimination

Travoprost is rapidly eliminated from plasma, within one hour the concentration drops below the detection threshold (< 10 pg/ml).

Travoprost is excreted as inactive metabolites mainly in the bile (61%), the rest is excreted by the kidneys.

Indications

Travathan is used in the treatment of open-angle glaucoma as well as to decrease intraocular pressure in patients with increased ophthalmotonus.

Active ingredient

Composition

Active substance:

Travoprost 0.04 mg;

Supplementary substances:

Macrogoal glyceryl hydroxystearate (synonym: polyoxyethylene hydrogenated castor oil 40 – HCO-40);

benzalkonium chloride solution (equivalent to benzalkonium chloride);

p>dinatrium edetate;

boric acid;

trometamol;

mannitol;

sodium hydroxide and/or hydrochloric acid concentrated to adjust the pH;

water purified.

How to take, the dosage

In the conjunctival sac. 1 drop once a day, in the evening. More frequent use may decrease the effectiveness of the drug.

Interaction

Travatan may be used in combination with other topical ophthalmic drugs to reduce intraocular pressure.

In this case the interval between their application should be at least 5 minutes.

Special Instructions

Permanent heterochromia may result from treatment in only one eye.

In the presence of nevi or lentigines on the iris, no change has been noted with the drug.

The drug may cause darkening, thickening and lengthening of eyelashes and/or increase in their number; rarely – darkening of the eyelid skin.

If Travatan is used with other anti-glaucoma drugs for topical use, the interval between applications should be at least 5 minutes.

It is recommended that contact lenses should always be removed before applying the medication to avoid impairing the transparency of the contact lenses. Do not put them back in until at least 20 min after the procedure.

The bottle should be closed after each use.

The product may cause a gradual discoloration of the eye by increasing the amount of brown pigment in the iris. This effect is mainly seen in patients with mixed coloration of the iris, such as blue-brown, gray-brown, green-brown, or yellow-brown, due to the increased melanin content of the stromal melanocytes in the iris. Brown pigmentation usually spreads concentrically around the pupil to the periphery of the iris, and the entire iris or portions of the iris may become more intensely brown.

In patients with uniformly blue, gray, green or brown colored eyes, changes in eye color after two years of use have been very rare. The color change was not accompanied by any clinical symptoms or pathological changes.

There has been no further increase in brown pigment after withdrawal of the drug, but the color change that has already developed may be irreversible.

People should be informed of the possibility of eye discoloration before starting treatment.

Contraindications

Travatan eye drops are not used in case of individual hypersensitivity to the drug components, during pregnancy and lactation as well as for the treatment of patients under 18 years of age.

With caution: risk factors for macular edema (aphakia, pseudophakia, damage of the posterior capsule of the lens), acute iritis, uveitis.

Side effects

In 35% of cases there is a transient mild conjunctival hyperemia, which passes without additional therapy over time.

In 5-10% of cases – decreased visual acuity, a feeling of discomfort and “foreign body feeling”, pain, itching, burning sensations in the eyes.
In 1-4% of cases – visual disorders, blepharitis, “fog” before eyes, cataract, conjunctivitis, dry conjunctiva, changes in iris coloration, keratitis, crusts formation on the eyelid edges, photophobia, subconjunctival hemorrhages and increased tear discharge.

Systemic side effects seen in 1-5% of cases: general restlessness, headache, depression, increased or decreased BP, bradycardia, angina pectoris, chest pain, arthritis, back pain, flu-like syndrome, sinusitis, bronchitis, hypercholesterolemia, dyspepsia, urinary incontinence and urinary system infections.

Overdose

Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episclera.

Treatment: symptomatic.

Pregnancy use

Travatan is contraindicated in women during pregnancy.

There is no sufficient experience of using the drug during breastfeeding. It is possible to use Travatan for treatment of breastfeeding mothers by prescription of the attending physician if the expected therapeutic effect exceeds the risk of possible side effects for the baby.

Pediatric use

The drug is contraindicated in children and adolescents under 18 years of age.

Similarities